Bispecific antibody · Immune activation, directed at Programmed cell death 1 ligand 1 (CD274) and CD27 molecule (CD27) · developed by Celldex Therapeutics
CDX-527 is a bispecific antibody that binds PD-L1 on tumor cells and CD27 on immune cells, including most T-lymphocytes. It blocks PD-L1 binding to PD-1 while stimulating CD27 signaling to enhance T-cell activation and cytotoxic T-lymphocyte responses. It is being studied in multiple solid tumors, including non-small cell lung, breast, gastric, renal cell, ovarian and head and neck cancers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04440943 | Phase 1 | Non-small Cell Lung Cancer | Completed | CLDX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Bladder Urothelial CarcinomaBreast CancerCholangiocarcinomaEsophageal CancerFallopian Tube CancerGastric CancerHead and Neck CancerHepatic CancerMSI-H Colorectal CancerNon-small Cell Lung CancerOther Solid TumorsOvarian CancerPrimary Peritoneal CarcinomaRenal Cell Carcinoma
Updated Oct 11, 2026. Something wrong or missing? Report it on the CLDX page.
See CLDX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CLDX catalysts and pipeline →